Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

Aptevo Therapeutics (APVO) has entered into definitive ... a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant. The warrants issued pursuant ...

TG Therapeutics (TGTX) announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis ...

Adaptimmune Therapeutics stock opened at $0.26 on Friday. The stock’s 50 day moving average is $0.47 and its 200 day moving average is $0.64. Adaptimmune Therapeutics has a one year low of $0.20 ...

Finally, Two Sigma Advisers LP acquired a new position in Rani Therapeutics in the 4th quarter worth about $151,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.

The global canine flu therapeutics market is set for substantial growth, with projections estimating a market value of USD 3.06 billion by 2033. The market, which was valued at USD 2.04 billion in ...

The stock price didn't jump after Gyre Therapeutics, Inc. ( NASDAQ:GYRE ) posted decent earnings last week. We did ...

Cintas Corporation CTAS shares jumped over 8% on Wednesday after the company posted better-than-expected third-quarter ...

Investing.com -- Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE ...

Outlook Therapeutics, Inc. (NASDAQ ... In addition, the stockholders approved the potential issuance of more than 19.99% of the company’s outstanding common stock upon the conversion of a ...

Valo Therapeutics Oy announces that it has successfully secured a financing round of €19 million, part of which was raised in Europe and part in Australia, to clinically develop its innovative immune ...